Published in J Clin Oncol on February 20, 2006
A review of reporting of participant recruitment and retention in RCTs in six major journals. Trials (2009) 1.64
Increasing trial generalizability. J Clin Oncol (2006) 1.03
An institutional strategy to increase minority recruitment to therapeutic trials. Cancer Causes Control (2013) 1.02
Endorsement of the CONSORT statement by high-impact medical journals in China: a survey of instructions for authors and published papers. PLoS One (2012) 0.94
Reporting of participant flow diagrams in published reports of randomized trials. Trials (2011) 0.89
Representativeness of two sampling procedures for an internet intervention targeting cancer-related distress: a comparison of convenience and registry samples. J Behav Med (2013) 0.88
Using an automated recruitment process to generate an unbiased study sample of multiple sclerosis patients. Telemed J E Health (2010) 0.80
Recruitment bias in chronic pain research: whiplash as a model. Clin Rheumatol (2011) 0.76
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. Trials (2016) 0.75
Predicting Participation in Psychiatric Randomized Controlled Trials: Insights From the STEP-BD. Psychiatr Serv (2015) 0.75
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol (2006) 6.24
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancer. J Clin Oncol (2011) 5.67
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2013) 5.56
American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol (2007) 5.36
HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med (2006) 5.10
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 4.94
Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med (2010) 4.63
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol (2005) 3.42
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol (2007) 3.12
Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol (2011) 3.05
Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med (2009) 2.88
Beyond the development of quality-of-life instruments: where do we go from here? J Clin Oncol (2002) 2.81
Venous thromboembolism and cancer: risks and outcomes. Circulation (2003) 2.68
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol (2004) 2.43
Assessing the volume-outcome hypothesis and region-level quality improvement interventions: pancreas cancer surgery in two Canadian Provinces. Ann Surg Oncol (2010) 2.16
Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol (2013) 1.99
A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. Transfusion (2002) 1.98
Why cancer patients enter randomized clinical trials: exploring the factors that influence their decision. J Clin Oncol (2004) 1.80
Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol (2006) 1.67
Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study. J Clin Oncol (2012) 1.58
Funding oncology clinical trials: are cooperative group trials sustainable? J Clin Oncol (2012) 1.56
Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol (2013) 1.54
A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol (2004) 1.54
Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin Cancer Res (2012) 1.47
Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer (2010) 1.47
Factors that influence the recruitment of patients to Phase III studies in oncology: the perspective of the clinical research associate. Cancer (2002) 1.45
The association of the palliative performance scale and hazard of death in an ambulatory cancer population. J Palliat Med (2012) 1.41
A systematic review of studies evaluating diffusion and dissemination of selected cancer control interventions. Health Psychol (2005) 1.36
Clinician-patient communication: a systematic review. Support Care Cancer (2009) 1.27
Registries that show efficacy: good, but not good enough. J Clin Oncol (2008) 1.25
Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2011) 1.20
Positron emission tomography-computed tomography compared with invasive mediastinal staging in non-small cell lung cancer: results of mediastinal staging in the early lung positron emission tomography trial. J Thorac Oncol (2011) 1.17
Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol (2008) 1.11
Adjuvant chemotherapy for breast cancer--30 years later. N Engl J Med (2006) 1.09
Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care (2011) 1.05
Do high symptom scores trigger clinical actions? An audit after implementing electronic symptom screening. J Oncol Pract (2012) 1.01
Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol (2004) 1.00
Towards improving the co-ordination of supportive cancer care services in the community. Health Policy (2004) 1.00
Who is responsible? The role of family physicians in the provision of supportive cancer care. J Oncol Pract (2009) 0.99
The cluster-randomized Quality Initiative in Rectal Cancer trial: evaluating a quality-improvement strategy in surgery. CMAJ (2010) 0.95
Systematic review: conservative treatments for secondary lymphedema. BMC Cancer (2012) 0.93
The Quality Initiative in Rectal Cancer (QIRC) trial: study protocol of a cluster randomized controlled trial in surgery. BMC Surg (2008) 0.93
Factors Associated with End-of-Life Health Service Use in Patients Dying of Cancer. Healthc Policy (2010) 0.93
Multidisciplinary health care professionals' perceptions of the use and utility of a symptom assessment system for oncology patients. J Oncol Pract (2011) 0.92
Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol (2011) 0.92
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat (2014) 0.92
Are family physician visits and continuity of care associated with acute care use at end-of-life? A population-based cohort study of homecare cancer patients. Palliat Med (2013) 0.91
Three-year outcomes of a Canadian multicenter study of accelerated partial breast irradiation using conformal radiation therapy. Int J Radiat Oncol Biol Phys (2010) 0.91
First experience with a novel robotic remote catheter system: Amigo™ mapping trial. J Interv Card Electrophysiol (2013) 0.90
What constitutes a "clinical trial"?: a survey of oncology professionals. Trials (2008) 0.89
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Res Treat (2011) 0.88
Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. Can J Surg (2009) 0.88
Opioid prescription after pain assessment: a population-based cohort of elderly patients with cancer. J Clin Oncol (2012) 0.88
Expectant management versus immediate treatment for low-grade cervical intraepithelial neoplasia : a randomized trial in Canada and Brazil. Cancer (2010) 0.87
Core domains for a person-focused outcome measurement system in cancer (PROMS-Cancer Core) for routine care: a scoping review and Canadian Delphi Consensus. Value Health (2013) 0.87
Do patient-reported symptoms predict emergency department visits in cancer patients? A population-based analysis. Ann Emerg Med (2013) 0.86
Cost effectiveness of a survivorship care plan for breast cancer survivors. J Oncol Pract (2013) 0.86
Coordination of palliative cancer care in the community: "unfinished business". Support Care Cancer (2009) 0.86
Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol (2009) 0.84
Modeling the longitudinal transitions of performance status in cancer outpatients: time to discuss palliative care. J Pain Symptom Manage (2012) 0.84
Surgical outcomes in women with ovarian cancer. Can J Surg (2008) 0.84
Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb (2011) 0.83
Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs. Qual Life Res (2014) 0.83
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl (2014) 0.82
Thrombotic disorders: diagnosis and treatment. Hematology Am Soc Hematol Educ Program (2003) 0.82
Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Res Treat (2015) 0.82
A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer. Support Care Cancer (2013) 0.82
Advanced lung cancer patients' experience with continuity of care and supportive care needs. Support Care Cancer (2012) 0.82
Trastuzumab cardiac side effects: only time will tell. J Clin Oncol (2005) 0.81
Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Res Treat (2007) 0.81
Pilot study of the quality initiative in rectal cancer strategy. Dis Colon Rectum (2004) 0.81
Researching the cost of research. J Clin Oncol (2003) 0.80
Of time and troubles: patient involvement and the production of health care disparities. Health (London) (2011) 0.80
Cancer patients' function, symptoms and supportive care needs: a latent class analysis across cultures. Qual Life Res (2014) 0.79
Uptake of an innovation in surgery: observations from the cluster-randomized Quality Initiative in Rectal Cancer trial. Can J Surg (2013) 0.79
Individual radiosensitivity and its relevance to health physics. Dose Response (2007) 0.79
Empirical comparison of methods for analyzing multiple time-to-event outcomes in a non-inferiority trial: a breast cancer study. BMC Med Res Methodol (2013) 0.79
Regional Nodal Irradiation in Early-Stage Breast Cancer. N Engl J Med (2015) 0.79
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: a phase II randomized study. Thromb Res (2012) 0.78
Research in cancer care disparities in countries with universal healthcare: mapping the field and its conceptual contours. Support Care Cancer (2014) 0.76
Anti-Xa effect of a low molecular weight heparin (dalteparin) does not accumulate in extended duration therapy for venous thromboembolism in cancer patients. Thromb Haemost (2005) 0.76
A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood (2010) 0.76
Patterns of use and outcomes for radiation therapy in the Quality Initiative in Rectal Cancer (QIRC) trial. Can J Surg (2013) 0.76
Providing supportive care to cancer patients: a study on inter-organizational relationships. Int J Integr Care (2008) 0.76
neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part II. J Clin Oncol (2003) 0.75
Conventional and complementary therapies: a tale of two research standards? J Clin Oncol (2010) 0.75
Technology resource planning in radiation oncology: application of a needs-based analytic framework to radiosurgery planning in Ontario. J Oncol Pract (2012) 0.75
Unforeseen complication of brachytherapy. CMAJ (2004) 0.75
Selective application of a test based on risk: using limited resources wisely. J Clin Oncol (2013) 0.75
Method to our madness or madness in our methods? Pitfalls in trial methodology. J Clin Oncol (2012) 0.75
What is the role for antithrombotics in cancer care? Interactive session with panel discussion. Cancer Treat Rev (2002) 0.75
Initiation of chemotherapy in cancer patients with poor performance status: a population-based analysis. J Palliat Care (2014) 0.75
Robotic radiosurgery for the treatment of 1-3 brain metastases: a pragmatic application of cost-benefit analysis using willingness-to-pay. Technol Cancer Res Treat (2013) 0.75
Symptom clusters in a population-based ambulatory cancer cohort validated using bootstrap methods. Eur J Cancer (2012) 0.75